AstraZeneca (AZN) PT Set at GBX 5,500 by JPMorgan Chase

AstraZeneca (LON:AZN) has been given a GBX 5,500 ($77.74) price target by research analysts at JPMorgan Chase in a research note issued to investors on Friday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. JPMorgan Chase’s price objective suggests a potential upside of 9.39% from the company’s previous close.

A number of other research analysts also recently commented on the company. Shore Capital reissued a “hold” rating on shares of AstraZeneca in a report on Wednesday. Deutsche Bank reissued a “buy” rating on shares of AstraZeneca in a report on Monday. Morgan Stanley reissued an “equal weight” rating and issued a GBX 5,250 ($74.20) price target on shares of AstraZeneca in a report on Tuesday, March 27th. BNP Paribas reissued an “outperform” rating and issued a GBX 5,600 ($79.15) price target on shares of AstraZeneca in a report on Thursday, March 22nd. Finally, Credit Suisse Group reissued an “outperform” rating and issued a GBX 5,800 ($81.98) price target on shares of AstraZeneca in a report on Tuesday, March 20th. Four investment analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. AstraZeneca has a consensus rating of “Hold” and a consensus target price of GBX 5,224.70 ($73.85).

Shares of AZN opened at GBX 5,028 ($71.07) on Friday. AstraZeneca has a one year low of GBX 4,260 ($60.21) and a one year high of GBX 5,520 ($78.02).

In related news, insider Philip A. J. Broadley purchased 415 shares of the company’s stock in a transaction dated Friday, February 2nd. The shares were acquired at an average cost of GBX 4,846 ($68.49) per share, for a total transaction of £20,110.90 ($28,425.30).

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.

Leave a Reply